Literature DB >> 12853773

Erectile dysfunction in the cardiac patient: how common and should we treat?

Robert A Kloner1, Stephanie H Mullin, Thomas Shook, Ray Matthews, Guy Mayeda, Steve Burstein, Harry Peled, Charles Pollick, Ranji Choudhary, Raymond Rosen, Harin Padma-Nathan.   

Abstract

PURPOSE: Risk factors for erectile dysfunction (ED) (hypertension, diabetes, smoking, lipid abnormality) are also risk factors for coronary artery disease. However, most cardiologists do not routinely ask about ED and patients often are reluctant or embarrassed to discuss it. We determined how common ED was in a group of patients with chronic stable coronary artery disease.
MATERIALS AND METHODS: We administered the validated Sexual Health Inventory for Men (SHIM) 5-item questionnaire, based on the International Index of Erectile Function questionnaire, to 76 men with chronic stable coronary artery disease during routine outpatient cardiology visits. Most of these men had not previously discussed ED with their cardiologist.
RESULTS: The mean patient age was 64 years (range 40 to 82). The questionnaire took about 5 minutes to complete. Of the patients 47% were on beta blockers, 92% statins, 28% diuretics. SHIM score was 21 or less in 53 men (70%), which is indicative of ED. Of the patients 75% had some difficulty achieving erections (question 2) and 67% had some difficulty maintaining an erection after penetration (question 3). The questionnaire reflected successful sildenafil treatment in 4 patients (SHIM scores 23 to 25). If these 4 men are included as having had ED then 57 of 76 (75%) had ED or recent history of ED.
CONCLUSIONS: ED is extremely common in men with chronic coronary artery disease (affecting approximately 75%) yet most cardiologists do not ask about it. The SHIM is a useful, quick and inexpensive tool for discussion and diagnosis of ED in this population. Although it is well established that cardiovascular risk factors are associated with erectile dysfunction, once it is present there is mixed information on whether treating the risk factors will treat the ED. Problems appear to be that lifestyle modification in midlife may simply be too late to effect a change, and some antihypertensive and lipid lowering drugs may actually exacerbate ED. Oral therapy for ED, namely the PDE5 inhibitors, is effective and safe in most cardiac and hypertensive patients. Organic nitrates such as nitroglycerin remain a contraindication to the concomitant use of these drugs. Guidelines for treatment of ED in the cardiac patient issued by the American College of Cardiology/American Heart Association and Princeton Guidelines may be useful in the approach to the cardiac patient with ED.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853773     DOI: 10.1097/01.ju.0000075055.34506.59

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

Review 1.  Should patients with erectile dysfunction be evaluated for cardiovascular disease?

Authors:  Kenneth A Ewane; Hao-Cheng Lin; Run Wang
Journal:  Asian J Androl       Date:  2011-11-28       Impact factor: 3.285

2.  Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis.

Authors:  Alexander W Pastuszak; Daniel A Hyman; Naveen Yadav; Guilherme Godoy; Larry I Lipshultz; Andre B Araujo; Mohit Khera
Journal:  J Sex Med       Date:  2015-03-02       Impact factor: 3.802

Review 3.  Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

Authors:  Vincent M Santillo; Franklin C Lowe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  ED and quality of life in CABG patients: an intervention study using PRECEDE-PROCEED educational program.

Authors:  S Pournaghash-Tehrani; S Etemadi
Journal:  Int J Impot Res       Date:  2013-06-13       Impact factor: 2.896

Review 5.  Emerging role for TNF-α in erectile dysfunction.

Authors:  Fernando S Carneiro; Robert Clinton Webb; Rita C Tostes
Journal:  J Sex Med       Date:  2010-12       Impact factor: 3.802

6.  Erectile dysfunction and coronary artery calcification in incident dialysis patients.

Authors:  Neil Roy; Sylvia Eleni Rosas
Journal:  J Nephrol       Date:  2021-03-08       Impact factor: 3.902

Review 7.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

8.  General practitioner views about discussing sexual issues with patients with coronary heart disease: a national survey in Ireland.

Authors:  Molly Byrne; Sally Doherty; Hannah M McGee; Andrew W Murphy
Journal:  BMC Fam Pract       Date:  2010-05-25       Impact factor: 2.497

Review 9.  Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Antonio Martín Morales; Vincenzo Mirone; John Dean; Pierre Costa
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

10.  Dimethylarginine dimethylaminohydrolase in rat penile tissue: reduced enzyme activity is responsible for erectile dysfunction in a rat model of atherosclerosis.

Authors:  K Park; D G Lee; S W Kim; J-S Paick
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.